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BACKGROUND: Supradiaphragmatic radiotherapy (SRT) to treat Hodgkin’s lymphoma (HL) at a young age increases the risk of breast
cancer (BC). A national notification risk assessment and screening programme (NRASP) for women who were treated with SRT
before the age of 36 years was instituted in the United Kingdom in 2003. In this study, we report the implementation and screening
results from the largest English Cancer Network.
METHODS: A total of 417 eligible women were identified through cancer registry/hospital databases and from follow-up (FU) clinics.
Screening results were collated retrospectively, and registry searches were used to capture BC cases.
RESULTS: Of the 417 women invited for clinical review, 243 (58%) attended. Of these 417 women, 23 (5.5%) have been diagnosed
with BC, a standardised incidence ratio of 2.9 compared with the age-matched general population. Of five invasive BCs diagnosed
within the NRASP, none involved axillary lymph nodes compared with 7 of 13 (54%) diagnosed outside the programme (Po0.10).
The mean latency for BC cases was 19.5±8.35 years and the mean FU duration for those unaffected by BC was 14.6±9.11 years
(Po0.01), suggesting that those unaffected by BC remain at high risk. Recall and negative biopsy rates were acceptable (10.5 and
0.8%, respectively).
CONCLUSIONS: The NRASP appears to detect BC at an early stage with acceptable biopsy rates, although numbers are small.
Determination of NRASP results on a national basis is required for the accurate evaluation of screening efficacy in women previously
treated with SRT.
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Treatment of Hodgkin lymphoma (HL) with supradiaphragmatic
radiotherapy (SRT) at a young age increases the incidence of
second cancers and non-malignant co-morbidities in later life
(Greenfield et al, 2006). Cohort studies have shown the 25-year
cumulative risk of breast cancer (BC) in women who were treated
with SRT in childhood and young adulthood to be approximately
10–33%, compared with a lifetime risk in the female UK popula-
tion of 11% (Department-of-Health, 2003; Taylor et al, 2007;
Cooper and Westlake, 2008). The relative risk (RR) is greatest in
women treated with SRT during adolescence and young adulthood,
although an increase in risk is shown in most studies with SRT up
to the age of 30–40 years, which persists for at least 20–25 years
after treatment (Tucker et al, 1988; Hancock et al, 1993; Bhatia
et al, 1996; Mauch et al, 1996; Aisenberg et al, 1997; Metayer et al,
2000; Swerdlow et al, 2000; Foss Abrahamsen et al, 2002; Ng et al,
2002; Travis et al, 2003; van Leeuwen et al, 2003; Taylor et al,
2007). The iatrogenic induction of a threefold increase in the RR
of a common cancer, with major health, social and economic
burdens, prompted the launch of a UK-wide national notification
risk assessment and screening programme (NRASP) in November
2003 (Department-of-Health, 2003). In this study, we report the
implementation and results of this exercise in the Greater
Manchester and Cheshire Cancer Network (GMCCN) the
largest Cancer Network in England serving a population of
3.2 million people.
MATERIALS AND METHODS
Patient identification and contact
The NRASP was launched in November 2003. In our centre, the
North Western Cancer Registry (NWCR) and databases of The
Christie (CHD; from 1965) were interrogated to identify eligible
women residing in the GMCCN and/or managed at The Christie.
An NWCR search was also completed of all patients within this Received 30 March 2009; revised 16 June 2009; accepted 3 July 2009
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scohort who had subsequently developed BC. Patients fulfilling all
search criteria were entered into the National Strategic Tracing
Service, and a letter was sent to their general practitioners (GPs)
to verify their current status and contact details. Invitation letters
were sent in November 2003, and again in March 2004 if no
reply was received. A telephone help line to provide informa-
tion about the NRASP, to answer queries and to facilitate an
appropriate recall of patients was staffed by experienced nurses
for 3 weeks.
Screening plan
Screening protocols for this exercise were established and the
rationale was subsequently published by a national expert com-
mittee (Table 1; Ralleigh and Given-Wilson (2004); Faulkner and
Law (2005)). Screening was to begin in women who were X8 years
after SRT and at least 25-years-old, whichever occurred later. Five
mammography and two magnetic resonance imaging (MRI)
centres with sufficient capacity were identified within the GMCCN.
It was agreed on a national basis that women would be screened by
the network serving their current residence, even if treated for HL
in a different network.
Patient review
Patients were reviewed at routine HL follow-up (FU) clinics or at
one of nine specially convened evening clinics. Consultations
covered explanations of the risk and appropriate screening
programme and, after informed consent, completion of a national
questionnaire to capture data on risk factors for secondary cancers
after HL treatment. Data were collected with regard to the dose and
date of SRT, chemotherapy regimen, relapse status and diagnosis
of other secondary malignancies. Simple cancer prevention and
health education strategies, such as smoking cessation, were also
discussed. An individual screening plan conforming to the national
guidelines was constructed for each woman and communicated to
their GP by letter (Table 1).
Data collection
In total, 29 screening units were contacted in August 2007 to
request screening results for all women who entered the NRASP
in 2003, whether they were being screened annually or every
3 years as part of the National Health Breast Screening Pro-
gramme (NHSBSP). For cases in which no results were forth-
coming, hospital notes were searched and/or GPs were contacted
for screening reports. The NWCR was interrogated for diagnoses
of invasive and in situ breast carcinomas in the women eligible for
inclusion in the study, and clinical notes of these patients were
reviewed to extract clinicopathological data on their BC diagnoses
and previous treatment details for HL.
Statistical analysis
The expected number of BC cases in the study population was
derived by multiplying each individual’s years at risk by age-
standardised crude incidence rates (of in situ and invasive BC).
Incidence rates were available for the GMCCN from 1985 to 2005 and
for England and Wales from 1967 to 1984. Data for 1963–1966 and
for 2006–2008 were not available, and the annual rates for 1967 and
2005, respectively, were used for these periods. The standardised
incidence rate (SIR) was expressed as the ratio of observed to
expected number of BC cases. Mean ages and radiotherapy doses
were compared using Student’s test, with adjusted degrees of
freedom for unequal variances wherever appropriate. Frequency
proportions between two groups were analysed using 2 2
contingency tables using the w
2 test with Yates’ continuity correction
or Fisher’s exact test wherever appropriate. SPSS package (SPSS
Woking, Surrey, UK) was used for these calculations.
RESULTS
Patient identification and review
Database searches revealed 405 eligible women and a further
15 were identified through the telephone helpline or FU clinics,
having received SRT at another institution but now residing in
the GMCCN. The processing of these women is described in
Figure 1 and, out of a total of 417 eligible patients, 243 (58%) were
reviewed, counselled and referred for screening if required.
Breast cancer risk
In the cohort of 417 women eligible for inclusion in the pro-
gramme, NWCR searches have identified 23 (5.5%) with at least
one diagnosis of breast malignancy. The expected number of cases
of BC in this population up to 2008 was 8.0, thus the SIR for
women treated with SRT for HL was 2.9. From the NRASP
inception, the SIR of BC in women as yet unaffected was 3.75
(O 6.0 /E 1.6) in those reviewed and 2 (O 3/E 1.5) in those not
reviewed. Table 2 presents the significant differences between these
two patient populations with regard to age at SRT, attained age
and years at risk of BC. Supradiaphragmatic radiotherapy field
characteristics did not differ between the two groups.
The women diagnosed with BC were considered as one cohort,
as no significant differences were found in the age at SRT, age at
NRASP, SRT dose or SRT field between the group that was
reviewed (n¼12) and the group that was not (n¼11; data not
shown). However, those with BC had a significantly higher mean
number of years for risk of BC (censored at first diagnosis of BC)
and were more likely to have received a mantle field and a higher
SRT dose than those without BC (Table 3).
Mantle field radiotherapy was delivered at a higher mean
dose (3416±474.0) compared with all other fields combined
(3018±707.5; Po0.0005). However, of the patients treated with
mantle field, there was no significant difference in dose between
those who did or did not develop BC (mean 3522±459.3 vs
3392±477.5; P¼0.32). The proportion of women receiving a
mantle field in each decade up to 2003 peaked at 70% during the
period 1974–1983, falling to 14% from 1994 to 2003.
Screening
Of the 243 eligible women who were reviewed, screening referrals
are outlined in Figure 1. None of the women who required
screening were aged o30 years and all were referred for
mammography in accordance with the protocol. One such woman
was screened with MRI alone because of local interpretation of
the protocol, and her MRI was reported as normal. All other
MRI scans were performed on young women to further evaluate
Table 1 Breast screening protocol for women treated with SRT for HL
aged o36 years
Attained age (years) Recommended surveillance
o25 No imaging
25–29 Annual MRI±ultrasound
a
30–50 Annual mammogram±MRI/ultrasound
b
450 3 yearly mammography on the NHSBSP
HL¼Hodgkin’s lymphoma; MRI¼magnetic resonance imaging; NHSBSP¼National
Health Service Breast Screening Programme; SRT¼supradiaphragmatic radio-
therapy.
aUltrasound to be used to further evaluate areas of suspicion on MRI.
bMRI or ultrasound to be used to further evaluate areas of suspicion on
mammography.
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smammographically normal but dense breasts, and were reported
as normal. Of the 210 patients referred for screening, 9 (4.3%)
subsequently declined and no evidence of screening could be
found for 30 (14.3%) patients. At the time of writing, 370 screening
results have been recovered for 171 of the 210 women (81%) in
whom screening should have been initiated, that is, a mean of
2.2 screens per patient (Table 4).
So far, 39 of 370 (10.5%) screening episodes have resulted in
patient recall, (Table 4) with 22 of 175 (12.6%) women being
recalled from their first screens and 17 of 195 (8.9%) from second
or subsequent screening episodes. In 31 of 39 screening episodes
that led to a recall, further mammographic views, USS or MRI was
considered adequate and these women remain BC free. Eight of
the 39 women underwent fine needle aspiration or core biopsy,
405 eligible women sent
letters of invitation
126(31%) Did not reply
24(6%) Declined review
255(63%) Accepted invitation
246*/270 women attended
for review
*3 found to be ineligible
15 additional women
identified via helpline
and FU clinics
Screening
deferred n=33
Screening on the
NHSBSP n=51
Immediate annual
screening n=159
Results obtained in
125/159 (79%)
Results obtained in
46/51 (91%)
Plan for screening
Figure 1 Flow diagram depicting the inclusion process for NRASP, the proportion of women requiring screening and the number of women for whom
screening reports were available. FU, follow-up; NHSBSP, National Health Service Breast Screening Programme.
Table 2 HL treatment and breast cancer risk demographics of women reviewed in the NRASP and those not reviewed
Women reviewed in
NRASP (n¼237)
Women not reviewed in
NRASP (n¼166) Significance value
Age at SRT (years±s.d.) 25.5±5.28 23.4±5.92 Po0.0005
Number treated with SRT aged o25 years (%) 116 (49) 106 (64) P¼0.002
Age at NRASP (years±s.d.) 40.3±9.09 43.2±11.81 P¼0.008
Average numbers of years at risk of BC (years±s.d.) 14.6±9.11 19.6±11.10 Po0.0001
SIR of breast cancer 3.75 (O 6.0/E 1.6) 2 (O 3/E 1.5) ND
BC¼breast cancer; HL¼Hodgkin’s lymphoma; ND¼not determined; NRASP¼notification risk assessment and screening programme; SRT¼supradiaphragmatic
radiotherapy.
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sand malignancy was confirmed in 5, giving a benign biopsy rate of
0.8% (3 of 364).
BC cases and tumour characteristics
The characteristics of each BC case, including both HL and BC
diagnosis and treatment, are presented in Table 5. Cases 3 and
6 were diagnosed with metachronous contralateral primary BCs
after March 2004, case 3b through the NHSBSP and case 6b by
palpation of an asymptomatic breast lump at a BC FU appoint-
ment. The latter BC was also visible by mammography. These
metachronous cancers are not included in subsequent analyses.
Three of the nine cases (15, 16 and 17) were diagnosed with BC
after the start of the NRASP but were not enrolled within it.
Five of the six women reviewed in the NRASP who developed BC
were diagnosed through the programme (cases 19–23, Table 5).
The sixth (case 18) had not attended the NHSBSP from the age
50 years, and presented symptomatically at age 56 years before
her first screen in the NRASP had been performed. This cancer
was also visible mammographically. Five of these six cases were
invasive ductal carcinomas (IDCs, cases 18–22), none of which
involved the axillary lymph nodes (ALNs). In contrast, in women
with early BC and known ALN status diagnosed outside the
NRASP, 7 of 13 (54%) involved ALNs (P¼0.10). Three of the cases
diagnosed within the NRASP were ‘triple negative’ for oestrogen
and progesterone receptors, as well as for HER-2, and two were
grade 3 tumours (Table 5). No significant differences were detected
in the median BC grade, size or oestrogen receptor expression in
those diagnosed within or outside the NRASP. The proportion of
women with a screen-detected BC was significantly higher in
women diagnosed after the inception of the NRASP (1 of 14 vs
6o f9 ;P¼0.01).
Breast cancer follow-up
In the eligible cohort of 417 women, 14 cases of BC were identified
as occurring before the inception of the NRASP, with a median
FU of 7 years. During this time, three patients suffered local
recurrence, two developed contralateral primary BC and one
developed metastatic BC from which she died. Two other women
with a diagnosis of BC are known to have died, one from another
secondary cancer (non-HL) and one from chronic obstructive
pulmonary disease. With a median FU of only 1 year, no
recurrence of BC has been seen in the cases identified through
the NRASP.
DISCUSSION
Through an assessment of the NRASP in the largest English cancer
network (GMCCN) with a population of 3.2 million, we have
confirmed that SRT at a young age increases the risk of BC
(SIR 2.9). This SIR is probably an underestimate of the true risk,
as we had no contact with 31% of eligible women. These women
may have been diagnosed with BC outside the GMCCN and such
cases would not have been identified by searches of the NWCR
alone. Indeed, this is likely to be the case as the risk factors for the
development of BC were increased in the group not reviewed and
the recorded SIR was lower than expected (Table 2). However, the
increased SIR of BC in the population reviewed in the NRASP may
also be due to a reduction in lead time after inception of the
screening programme. The impact of shortened lead time on BC
incidence will only be addressed appropriately by an examination
of the national annual BC incidence rates in the HL cohort over a
more protracted period of time.
In our cohort of 417 women, 243 (58%) attended for risk assess-
ment. In the only other Cancer Network to report implementation
results in this programme (North Trent), the uptake rate was
comparable at 64% (77 of 120) (Greenfield et al, 2006). Three
similar recall studies conducted in North America have published
recall rates of 32% (115 of 360) (Lee et al, 2008), 28% (47 of 167)
(Kwong et al, 2008) and 54% (90 of 167) (Diller et al, 2002). These
data demonstrate the difficulties inherent in this type of exercise
in which patients are contacted retrospectively, and argue strongly
for the prospective identification and counselling of such women
at completion of treatments known to be associated with late
toxicity.
Table 4 Results of screening tests performed as part of the NRASP
(including those screens performed on the NHSBSP in women X50 years)
Screening finding Number of screens (%)
Normal screen 315 (86.5)
Dense breasts on mammography – USS/MRI 20 (5.5)
Abnormal – further imaging but no malignancy 21 (5.8)
Abnormal – FNA or core biopsy but no malignancy 3 (0.8)
Abnormal – DCIS confirmed 1 (0.3)
Abnormal – invasive malignancy confirmed 4 (1.1)
Total 364 (100)
DCIS¼ductal carcinoma in situ;F N A ¼fine needle aspiration; MRI¼magnetic
resonance imaging; NHSBSP¼National Health Service Breast Screening Programme;
NRASP¼notification risk assessment and screening programme; USS¼ultrasound
scan.
Table 3 Age and HL treatment demographics for women reviewed in the NRASP and for those diagnosed with BC
Women reviewed in NRASP
excluding BC cases n¼ 231
BC cases
n¼23
Significance
value
Mean age at SRT (years±s.d.) 25.6±5.25 23.4±5.08 P¼0.06
Number o25 years at SRT (%) 113 (49) 15 (65)
Mean age at NRASP (years±s.d.)
a 40.1±9.11 45.3±8.66 P¼0.01
Mean number of years at risk of BC at NRASP inception (±s.d.)
a 14.6±9.11 19.5±8.35 P¼0.01
Number with SRT field (%)
b
Mantle 83 (34) 16 (70)
Mediastinal 139 (57) 5 (22)
Other 21 (8) 2 (9) Po0.0005
c
Mean SRT dose (±s.d.) (cGy)
d 3137 (±676.9) 3367 (±449) P¼0.005
Alkylating chemotherapy (%)
e 188/219 (86) 17/23 (74) P¼0.23
BC¼breast cancer; HL¼Hodgkin’s lymphoma; NRASP¼notification risk assessment and screening programme; SRT¼supradiaphragmatic radiotherapy.
aCensored at the time
of diagnosis of BC.
bSRT field data not available for four patients.
cComparing mantle field and others combined.
dSRT dose unknown in seven patients.
eChemotherapy details
not known for 12 patients.
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sThe primary goal of breast screening is to reduce BC mortality
through early detection. The sensitivity and specificity of the
screening programme should be optimised to minimise the
psychological and physical morbidity associated with false-positive
diagnoses. The majority of retrospective data suggests that BC
occurring after SRT is detectable by mammography in 80–100%
of cases (Dershaw et al, 1992; Yahalom et al, 1992; Tardivon et al,
1999; Ralleigh and Given-Wilson, 2004). The degree of sensitivity
in a relatively young population is believed to be due to a high
prevalence of micro-calcification associated with abnormal mam-
mograms. However, these data are limited by small sample sizes
and absent age-matched controls. In the three prospective recall
studies from North America, 27 of 28 (96%) of the BCs diagnosed
were evident on mammography (Diller et al, 2002; Kwong et al,
2008; Lee et al, 2008). After the inception of the NRASP in the
GMCCN, no interval cancers have been diagnosed, five of six
women who consented to screening and developed BC were
diagnosed by mammography and the sixth presented symptoma-
tically with a mammographically detectable invasive cancer before
routine screening was initiated. Furthermore, the five additional
women diagnosed with BC during the NRASP (cases 3b, 6b and
15–17; Table 5) all had BCs visible on mammography, although
three of five (cases 6b, 16 and 17) presented symptomatically.
These data and the lack of ALN involvement in all of the BCs
detected through the NRASP suggest that the screening strategy is
appropriate, although the number of cases is small.
In contrast, Lee et al (2008) found that six of seven invasive
cancers detected through their prospective screening clinic were
detected clinically. Although all but one of the seven BCs
were visible by mammography, four of the women had had
mammograms reported as normal within the preceding 6–12
months, and all of these women had ALN involvement (Lee et al,
2008). This group is currently examining the role of screening on
a 6-monthly basis, alternating between mammography and MRI
(Lee et al, 2008). The American Cancer Society has recommended
the use of MRI to screen women at high risk of BC after SRT for
HL in the absence of data demonstrating superior efficacy over
mammography in this specific population, although the potential
risks of additional small doses of radiation through mammo-
graphy must be considered (Saslow et al, 2007). In other high-risk
populations, MRI has demonstrated a significant improvement
in diagnostic sensitivity, but at the expense of reduced specificity
with increased recall (10–12%) and benign biopsy rates (Kriege
et al, 2004; Leach et al, 2005; Saslow et al, 2007). In this study,
the recall rate for first screens was 12.8% compared with 17.2%
(17 of 99) and 12.7% (10 of 79) in the two other studies in this
setting (Diller et al, 2002; NHSBSP, 2007; Kwong et al, 2008). The
rate is higher than that for NHSBSP (8.3% during 2005–2006),
almost certainly because of the younger age of the HL-screening
population (NHSBSP, 2007). Indeed, exclusion of the 10 cases who
were all o50 years of age and who were recalled for a reassessment
of normal dense breasts by further imaging alone results in a recall
rate of 6.9% (12 of 175). The benign biopsy rate in our report,
at 0.8% (3 of 364), was higher than that in the NHSBSP (0.2%),
perhaps reflecting the knowledge of the increased RR of this
population by reporting radiologists, or the relatively small patient
numbers in this study. No open biopsies were performed. The
benign biopsy rates in the two prospective screening studies that
Table 5 Individual cases of breast cancer in women treated with SRT for HL
Radiotherapy Pathology Immuno-phenotype BC treatment
Case
BC Latency
(years)
HL type
and stage
Dose
(cGy) Field SDBC ALN Subtype
Size
(mm) Grade ER/PR Her2
BC
Rec Chemo RT
1 25 NS 1a 3000 H+N N 0/7 IDC 40 2 ND ND N N CW
2 12 NS? 4100 M+SCF N 0/9 IDC 4 2 ND ND N N N
3a 16 NS 2b 3500 M N 0/8 IDC 40 3  /   NA C N
3b 29 Y 0/10 IDC 15 3  /   NN N
4 14 NS 3a 3500 M N 0/? IDC 5 2 ND ND N N N
5 12 NS 2b 3000 Med+N N 0/15 IDC 12 3  /  ND Y N B
6a 5 NS 2a 3500 M N 0/? DCIS NK — ND ND N N N
6b 14 N 0/7 DCIS 10 3  /  +NN N
7 10 NS 2a 3500 M N 1/7 IDC 22 2 +/+   YC M F N
8 21 NS 2a 3500 M N 6/14 IDC 39 3 +/- + Y CMF N
9 12 MC 3b 3500 M N 2/2 IDC 45 2 +/- ND N FEC N
10 23 MC 4b 3000 Med+N N 1/9 IDC 14 1 +/+ + Y N N
11 31 NS 4a 2500 M Y 0/14 IDC 6 3 +/+ ND N N N
12 16 NS 1a 3500 M N 0/? Sarcoma NK ND ND ND Y N N
13 32 NS 4b 3100 Med+N+Ax N ND ILC 28
a 2 +/+ ND N N N
14 17 MC 1a 3500 M N 10/17 IDC 24 2 +/+ + N FEC-D N
15a 20 NS 2a 3000 N+Ax Y 2/9 IDC 15 1 +/+ + N N N
15b Y IDC 14 3 +/+ +
15c Y 1/1 IDC 8 2 +/+ +
16 10 NS 4b 3000 Med N 1/12 IDC 110
a 2  /   NX DC W
17a 27 NS 3a 3000 M N ND Mucoid NK NK NK NK M N N
17b N ND IDC 40
a 3  /  
18 30 LP 1a 3000 M N 0/12 IDC 33 3  /   N E-CMF CW
19 14 NS 2a 3500 M Y 0/11 IDC 26 2 +/+ ND N N CW
20 33 MC 2 3000 Med+N Y 0/5 IDC 5 1 +/+ ND N N N
21 33 NS 2b 4750 M Y 0/1 IDC 17 2  /   NK NK NK
22 15 NS 2b 3500 M Y 0/15 IDC 15 3  /   NX D N
23 20 NS 2a 3500 M Y 0/4 DCIS 140 3  /   NN N
AC¼adriamycin cyclophosphamide; ALN¼axillary lymph node; Ax¼axilla; B¼breast; BC¼breast cancer; Chemo¼chemotherapy; CMF¼cyclophosphamide methotrexate
5-fluorouracil; CW¼chest wall; DCIS¼ductal carcinoma in situ;E R¼oestrogen receptor; FEC 5-fluorouracil epirubicin cyclophosphamide; H¼head; Her2¼human epidermal
growth factor receptor 2; HL¼Hodgkin lymphoma; IDC¼invasive ductal carcinoma; ILC¼invasive lobular carcinoma; LP¼lymphocyte predominant; M¼mantle; MC¼mixed
cellularity; Med¼mediastinum; N¼neck; NS¼nodular sclerosing; ND¼not determined; NK¼not known; PR¼progesterone receptor; Rec¼recurrence; RT¼radiotherapy;
SCF¼supraclavicular fossa; SDBC¼screen-detected BC; SRT¼supradiaphragmatic radiotherapy; XD¼capecitabine docetaxel.
aClinical measurement only.
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sreported this parameter were 3.8 and 6.1%, respectively (Diller
et al, 2002; NHSBSP, 2007; Kwong et al, 2008).
The risk of developing BC after treatment for HL is related to
both SRT dose and field (Tinger et al, 1997; Hill et al, 2005). In our
cohort, the increased SRT dose received by BC cases was primarily
a reflection of the increased incidence of a mantle field rather than
an independent effect of dose on BC development. At The Christie,
as elsewhere, the use of a mantle field for the treatment of women
requiring SRT for HL has declined over time. In a recent report, a
switch from a 35-Gy mantle field to involved field radiotherapy
(IFRT) at the same total dose reduced the estimated 20-year excess
RR of BC by 63% (Hodgson et al, 2007). This model is consistent
with meta-analysis data of clinical trials demonstrating an odds
ratio of 3.25 (P¼0.04) for the development of BC for women
treated with extended field vs IFRT (Franklin et al, 2006). It may
be possible to avoid radiotherapy altogether in a proportion of
patients with both early and advanced stage HL, thus reducing the
detrimental long-term sequelae of treatment for these individuals.
The challenge is to identify with precision those patients in whom
SRT is absolutely required for optimal disease control and those
in whom SRT can be safely omitted (Meyer et al, 2005; Diehl, 2007;
Eich et al, 2007; Picardi et al, 2007). Studies to determine the role
of FDG-PET imaging in this process are underway and promising
interim results have been reported (Radford et al, 2008).
The introduction of widespread screening in developed coun-
tries is in part responsible for the decrease in BC mortality
observed over the last 15–20 years (Nystrom et al, 2002; Berry
et al, 2005). Screening detects BC at an earlier stage, with lower
rates of ALN involvement, perhaps the most important of all
negative prognostic factors in BC (Rosen et al, 1989). However,
screening may also detect indolent cancers with little capacity to
impact negatively on health; moreover, the method of BC detection
(screening vs symptomatic) has itself recently been recognised as a
prognostic factor for BC recurrence (Joensuu et al, 2004; Shen
et al, 2005). In this study, 18 women with IDC or ILC had a known
ALN status. In all, 7 of 13 (54%) women outside the NRASP had
an ALN involvement compared with none (0 of 5) of those
reviewed within it. Thus, the NRASP strategy seems to be capable
of detecting BC at an early clinical stage, whereas the range of
immunophenotypes suggests that these tumours are not of a
universally good prognosis. Although new radiotherapy tech-
niques and treatment strategies have the potential to reduce the
future burden of late effects, the population of women reviewed
in the NRASP has a mean age approaching that at which BC
was diagnosed in the 23 affected women, suggesting that there
remains a significant cohort at an increased risk of BC (and other
malignancies) in whom continued vigilance is required (Tinger
et al, 1997; Hodgson et al, 2007).
CONCLUSIONS
This study indicates the qualified success of the NRASP in the
largest English Cancer Network. Although the detected cancers
were ALN negative, numbers are small and a national summing
of the results of the programme should be instituted to fully
evaluate all aspects of the screening strategy.
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